Head-to-head evidence
bb21217 vs Trovocabtagene autoleucel (C-CAR088)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Multiple Myeloma
Shared mechanism: BCMA · full Multiple Myeloma pipeline
bb21217
Developed by 2seventy bio, Inc. (wholly-owned subsidiary of Bristol Myers Squibb)
NCT03274219 · Phase 1 · completed
There was no control group and no blinding: everyone in the study received bb21217, and the trial was designed to check safety rather than measure effectiveness. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Trovocabtagene autoleucel (C-CAR088)
Developed by AbelZeta Pharma, Inc.
NCT03751293 · Phase 1 · status unknown
This is a very small, open-label, single-arm safety study of a cell therapy with no comparator group and no blinding, and results have not yet been posted.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: bb21217's landscape · Trovocabtagene autoleucel (C-CAR088)'s landscape